January 19, 2024 11:28 AM EST
People
R&D

Af­ter Bris­tol My­ers pulls out of col­lab­o­ra­tion, Ike­na On­col­o­gy lays off 35% of staff and trims can­cer pipeline

Anna Brown

News Reporter

Ike­na On­col­o­gy is cut­ting 35% of its work­ers to help fund two on­col­o­gy can­di­dates af­ter dump­ing two oth­er can­cer as­sets it was slat­ed to work …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times